Daniel E. Abbott, MD, FACS

Associate Professor

  • Surgical Director, UW Health Liver and Pancreas Center
  • Division of Surgical Oncology

Clinic: (608) 263-7502

  • Administrative Assistant: (608) 262-2025

600 Highland Avenue
Box 7375, Clinical Science Center
Madison, WI 53792


  • MD, University of Washington School of Medicine, Seattle, Washington, 2003
  • General Surgery Residency, Northwestern University/Feinberg School of Medicine, Chicago, Illinois, 2010
  • Research Fellowship, Children's Memorial Research Center/Northwestern University, Division of Cancer Biology and Epigenomics, Chicago, Illinois, 2008
  • Surgical Oncology Fellowship, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2012

Clinical Specialties

Dr. Abbott is certified by the American Board of Surgery and is a Fellow of the American College of Surgeons. Trained specifically in cancer surgery at The University of Texas MD Anderson Cancer Center, his clinical focus is on gastrointestinal malignancies, as well as melanoma and sarcoma. He performs both traditional and laparoscopic resections for cancers of the liver, pancreas, and stomach. As Director of Cytoreductive and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Surgery, he is particularly interested in patients with peritoneal spread of appendiceal, colorectal and ovarian cancers. Dr. Abbott is active in a number of national organizations, including the Society of Surgical Oncology, the American Hepatopancreaticobiliary Association, the Association for Academic Surgery, and the Society of University Surgeons.

Research Interests

Dr. Abbott, a health services researcher, focuses on cost-effectiveness, systems efficiency, and socioeconomic disparity in cancer care. He is particularly interested in identifying opportunities to maintain or enhance cancer care using technology in a patient-centered manner and thereby helping patients access expert cancer care in more personalized settings.

Recent Publications

  • Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors-There is hope, but more data are needed.
    Barrett JR, Abbott DE
    J Surg Oncol 2020 May 17;
    [PubMed ID: 32419171]

  • ASO Author Reflections: Predictors of Fiscal Outcomes in CRS-HIPEC and Opportunities for Improvement.
    Schwartz PB, Abbott DE
    Ann. Surg. Oncol. 2020 May 16;
    [PubMed ID: 32418080]

  • What Drives High Costs of Cytoreductive Surgery and HIPEC: Patient, Provider or Tumor?
    Schwartz PB, Stahl CC, Vande Walle KA, Pokrzywa CJ, Cherney Stafford LM, Aiken T, Barrett J, Acher AW, Leverson G, Ronnekleiv-Kelly S, Weber SM, Abbott DE
    Ann. Surg. Oncol. 2020 May 15;
    [PubMed ID: 32415351]

  • Summary perioperative risk metrics within the electronic medical record predict patient-level cost variation in pancreaticoduodenectomy.
    Stahl CC, Schwartz PB, Leverson GE, Barrett JR, Aiken T, Acher AW, Ronnekleiv-Kelly SM, Minter RM, Weber SM, Abbott DE
    Surgery 2020 Apr 26;
    [PubMed ID: 32349869]

  • Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study.
    Powers BD, Felder S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Staley CA, Maithel SK, Patel S, Dhar V, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Lee B, Johnston FM, Greer J, Cloyd JM, Kimbrough C, Grotz T, Leiting J, Fournier K, Lee AJ, Imanirad I, Dessureault S, Dineen SP
    Ann. Surg. Oncol. 2020 Apr 21;
    [PubMed ID: 32318945]

All Publications on PubMed